Completed PHASE3 INTERVENTIONAL NCT00182429

Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment

Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD)

Sponsor: McMaster University

Conditions Antibiotic-Associated Diarrhea Clostridium Enterocolitis Pseudomembranous Colitis Pseudomembranous Enteritis Pseudomembranous Enterocolitis

Interventions Metronidazole and Rifampin

Updated 6 times since 2017 Last updated: Aug 14, 2018 Started: Feb 29, 2004 Primary completion: Apr 30, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00182429, this PHASE3 trial focuses on Antibiotic-Associated Diarrhea and Clostridium Enterocolitis and remains completed. Sponsored by McMaster University, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

McMaster University
The Physicians' Services Incorporated Foundation

Data source: McMaster University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamilton, Canada